Showing 221 - 240 results of 18,435 for search 'significantly ((((we decrease) OR (a decrease))) OR (((greatest decrease) OR (mean decrease))))', query time: 0.64s Refine Results
  1. 221
  2. 222
  3. 223
  4. 224
  5. 225
  6. 226

    Flow chart of sediment P fractionation procedure. by Jiayu Hu (673291)

    Published 2025
    “…The NH<sub>4</sub>Cl-Po and NaHCO<sub>3</sub>-Po concentrations in sediments showed the greatest decrease (accounting for 97.6% of total decrease) during the experiment. …”
  7. 227
  8. 228
  9. 229
  10. 230

    Prolonged starvation leads to a delay in cell cycle re-entry and decrease in H3K27ac in Vasa2+/Piwi1+ cells. by Eudald Pascual-Carreras (12115380)

    Published 2025
    “…During starvation (T<sub>5ds</sub>, T<sub>20ds</sub>), MFI levels of H3K27ac progressively decreased <b>(F)</b> while levels H3K27me3 did not change significantly <b>(G)</b>. …”
  11. 231
  12. 232
  13. 233
  14. 234
  15. 235
  16. 236
  17. 237

    Data from: <b>Selection and genetic variation in plasticity drive age-related decreases in among-individual behavioural correlations</b> by Chang Seok Han (21814121)

    Published 2025
    “…In addition, genetic variation in age-related plasticity in exploration contributed to a decrease in the magnitude of genetic correlations during the adult stage. …”
  18. 238
  19. 239

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  20. 240

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”